Mechanistic targeting of advanced glycation end-products in age-related diseases

Biochim Biophys Acta Mol Basis Dis. 2018 Dec;1864(12):3631-3643. doi: 10.1016/j.bbadis.2018.08.036. Epub 2018 Aug 29.

Abstract

Glycative stress, caused by the accumulation of cytotoxic and irreversibly-formed sugar-derived advanced glycation end-products (AGEs), contributes to morbidity associated with aging, age-related diseases, and metabolic diseases. In this review, we summarize pathways leading to formation of AGEs, largely from sugars and glycolytic intermediates, and discuss detoxification of AGE precursors, including the glyoxalase system and DJ-1/Park7 deglycase. Disease pathogenesis downstream of AGE accumulation can be cell autonomous due to aggregation of glycated proteins and impaired protein function, which occurs in ocular cataracts. Extracellular AGEs also activate RAGE signaling, leading to oxidative stress, inflammation, and leukostasis in diabetic complications such as diabetic retinopathy. Pharmaceutical agents have been tested in animal models and clinically to diminish glycative burden. We summarize existing strategies and point out several new directions to diminish glycative stress including: plant-derived polyphenols as AGE inhibitors and glyoxalase inducers; improved dietary patterns, particularly Mediterranean and low glycemic diets; and enhancing proteolytic capacities of the ubiquitin-proteasome and autophagy pathways that are involved in cellular clearing of AGEs.

Keywords: Advanced glycation end-products; Age-related macular degeneration; Autophagy; Cataract; Diabetes; Diabetic retinopathy; Glyoxalase; RAGE; Ubiquitin-proteasome system.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Animals
  • Autophagy / drug effects
  • Cataract / drug therapy
  • Cataract / metabolism*
  • Cataract / pathology
  • Diabetic Retinopathy / drug therapy
  • Diabetic Retinopathy / metabolism*
  • Diabetic Retinopathy / pathology
  • Drug Discovery
  • Glycation End Products, Advanced / metabolism*
  • Humans
  • Macular Degeneration / drug therapy
  • Macular Degeneration / metabolism*
  • Macular Degeneration / pathology
  • Receptor for Advanced Glycation End Products / metabolism
  • Ubiquitin / metabolism

Substances

  • Glycation End Products, Advanced
  • Receptor for Advanced Glycation End Products
  • Ubiquitin